FDA Prioritizes Amivantamab Review in Head-and-Neck Cancer
FDA granted Priority Review to Johnson & Johnson’s supplemental application for subcutaneous amivantamab plus hyaluronidase in recurrent or metastatic head-and-neck squamous cell carcinoma after platinum chemotherapy and PD-1/PD-L1 therapy. The milestone accelerates review but…
